About: Helixmith

An Entity of Type: Public company, from Named Graph: http://dbpedia.org, within Data Space: dbpedia.org

Helixmith Co., Ltd. is a biotechnology company located in Seoul, Korea with US presence in San Diego. The company has an extensive gene therapy pipeline, including a non-viral plasmid DNA program for neuromuscular and ischemic disease, a CAR-T program targeting several different types of solid tumors, and an AAV vector program targeting neuromuscular diseases. Helixmith’s lead gene is Engensis (VM202), currently in phase III diabetic peripheral neuropathy (DPN) in the US. Engensis (VM202) is a plasmid DNA designed to simultaneously express two isoforms of hepatocyte growth factor (HGF), HGF 728 and HGF 723. In addition to DPN, Engensis is also being studied in diabetic foot ulcers (DFU), amyotrophic lateral sclerosis (ALS), coronary artery disease (CAD), claudication, and Charcot-Marie-Too

Property	Value
dbo:abstract	Helixmith Co., Ltd. is a biotechnology company located in Seoul, Korea with US presence in San Diego. The company has an extensive gene therapy pipeline, including a non-viral plasmid DNA program for neuromuscular and ischemic disease, a CAR-T program targeting several different types of solid tumors, and an AAV vector program targeting neuromuscular diseases. Helixmith’s lead gene is Engensis (VM202), currently in phase III diabetic peripheral neuropathy (DPN) in the US. Engensis (VM202) is a plasmid DNA designed to simultaneously express two isoforms of hepatocyte growth factor (HGF), HGF 728 and HGF 723. In addition to DPN, Engensis is also being studied in diabetic foot ulcers (DFU), amyotrophic lateral sclerosis (ALS), coronary artery disease (CAD), claudication, and Charcot-Marie-Tooth disease (CMT). (en)
dbo:formerName	Byromedica Pacific Co., Ltd. (en) ViroMed (en) (1996–1999) (en) (1999–2019) (en)
dbo:industry	dbr:Biotechnology
dbo:locationCity	dbr:Seoul
dbo:numberOfEmployees	121 (xsd:nonNegativeInteger)
dbo:product	https://www.helixmith.com/eng/s2/s2_1.php
dbo:subsidiary	https://www.helixmith.com/eng/s3/s3_1.php https://www.helixmith.com/eng/s3/s3_2.php
dbo:thumbnail	wiki-commons:Special:FilePath/Helixmith_Logo.jpg?width=300
dbo:type	dbr:Public_company
dbo:wikiPageExternalLink	https://www.helixmith.com/eng/s3/s3_1.php https://www.helixmith.com/eng/s2/s2_1.php https://www.helixmith.com/eng/s3/s3_2.php
dbo:wikiPageID	36294209 (xsd:integer)
dbo:wikiPageLength	10412 (xsd:nonNegativeInteger)
dbo:wikiPageRevisionID	1123025750 (xsd:integer)
dbo:wikiPageWikiLink	dbr:San_Diego dbr:Schwann_cells dbc:South_Korean_companies_established_in_1996 dbc:Pharmaceutical_companies_established_in_1996 dbr:Renal_disease dbr:Rheumatoid_arthritis dbr:C-MET dbr:CAR-T dbr:Public_company dbc:Biotechnology_companies_established_in_1996 dbr:Gene_therapy dbr:Ministry_of_Food_and_Drug_Safety dbr:Multiple_sclerosis dbr:Coronary_artery_disease dbr:Antibody dbr:Claudication dbr:Adeno-associated_virus dbr:Amyotrophic_lateral_sclerosis dbr:FDA dbr:Osteoarthritis dbc:Biotechnology_companies_of_South_Korea dbr:Diabetic_neuropathy dbr:KOSDAQ dbr:Half-life dbc:Biopharmaceutical_companies dbc:Companies_based_in_Seoul dbc:Life_sciences_industry dbc:South_Korean_brands dbr:Biotechnology dbr:Hepatocyte_growth_factor dbr:Neuromuscular_junction dbr:Seoul dbr:Seoul_National_University dbr:Plasmid dbr:Charcot-Marie-Tooth_disease dbr:Diabetic_foot_ulcers dbr:Neuromuscular_diseases dbr:File:Helixmith.jpg
dbp:formerName	(en) Byromedica Pacific Co., Ltd. (en) ViroMed (en)
dbp:founder	Sunyoung KIM, D. Phil (en)
dbp:hqLocationCity	Magok, Seoul (en)
dbp:hqLocationCountry	South Korea (en)
dbp:industry	dbr:Biotechnology
dbp:keyPeople	Sunyoung Kim , Seungshin Yu , Sinyoung Kim (en)
dbp:location	21 (xsd:integer)
dbp:logo	Helixmith Logo.jpg (en)
dbp:name	Helixmith (en)
dbp:numEmployees	121 (xsd:integer)
dbp:numEmployeesYear	2019 (xsd:integer)
dbp:products	https://www.helixmith.com/eng/s2/s2_1.php
dbp:subsid	https://www.helixmith.com/eng/s3/s3_1.php https://www.helixmith.com/eng/s3/s3_2.php
dbp:type	dbr:Public_company
dbp:wikiPageUsesTemplate	dbt:Advert dbt:Infobox_company dbt:Multiple_issues dbt:Short_description dbt:Start_date_and_age dbt:URL dbt:Unreferenced dbt:Use_American_English dbt:Use_mdy_dates
dcterms:subject	dbc:South_Korean_companies_established_in_1996 dbc:Pharmaceutical_companies_established_in_1996 dbc:Biotechnology_companies_established_in_1996 dbc:Biotechnology_companies_of_South_Korea dbc:Biopharmaceutical_companies dbc:Companies_based_in_Seoul dbc:Life_sciences_industry dbc:South_Korean_brands
rdf:type	owl:Thing dbo:Company schema:Organization dul:Agent dul:SocialPerson dbo:Agent wikidata:Q24229398 wikidata:Q43229 wikidata:Q4830453 dbo:Organisation
rdfs:comment	Helixmith Co., Ltd. is a biotechnology company located in Seoul, Korea with US presence in San Diego. The company has an extensive gene therapy pipeline, including a non-viral plasmid DNA program for neuromuscular and ischemic disease, a CAR-T program targeting several different types of solid tumors, and an AAV vector program targeting neuromuscular diseases. Helixmith’s lead gene is Engensis (VM202), currently in phase III diabetic peripheral neuropathy (DPN) in the US. Engensis (VM202) is a plasmid DNA designed to simultaneously express two isoforms of hepatocyte growth factor (HGF), HGF 728 and HGF 723. In addition to DPN, Engensis is also being studied in diabetic foot ulcers (DFU), amyotrophic lateral sclerosis (ALS), coronary artery disease (CAD), claudication, and Charcot-Marie-Too (en)
rdfs:label	Helixmith (en)
owl:sameAs	wikidata:Helixmith https://global.dbpedia.org/id/4xprC
prov:wasDerivedFrom	wikipedia-en:Helixmith?oldid=1123025750&ns=0
foaf:depiction	wiki-commons:Special:FilePath/Helixmith.jpg wiki-commons:Special:FilePath/Helixmith_Logo.jpg
foaf:isPrimaryTopicOf	wikipedia-en:Helixmith
foaf:name	Helixmith (en)
is dbo:wikiPageRedirects of	dbr:ViroMed
is dbo:wikiPageWikiLink of	dbr:ViroMed
is foaf:primaryTopic of	wikipedia-en:Helixmith